Protara Therapeutics (TARA) names William Conkling as Chief Commercial Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
June 2, 2025 4:04 PM EDTNEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William Bill Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara.
It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader, said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. With an impressive track record building commercial organizations and successfully... More
